Insmed (INSM) Return on Capital Employed (2011 - 2026)
Insmed (INSM) recorded quarterly Return on Capital Employed of 63.67% in Q1 2026, up 5.84% quarter-over-quarter from 67.62% in Q4 2025, and down 510.0% on a YoY basis from 15.53% in Q1 2025.
Insmed (INSM) Return on Capital Employed (2011 - 2026) Analysis & Trends
Insmed's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 63.67% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 510.0% year-over-year to 63.67%; the TTM figure through Mar 2026 stood at 63.67% (down 510.0% YoY), while the FY2025 annual figure was 74.39%, down 1075.0% from the prior year.
- Return on Capital Employed was 63.67% for Q1 2026 at Insmed, up from 67.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 35.51% in Q1 2022 to a low of 85.84% in Q1 2024.
- Historically, Return on Capital Employed has averaged 55.19% across 5 years, with a median of 54.92% in 2025.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 4898 bps in 2024, then jumped 2727 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 40.28% in 2022, then slumped by 60 bps to 64.41% in 2023, then rose by 22 bps to 50.43% in 2024, then tumbled by 34 bps to 67.62% in 2025, then increased by 6 bps to 63.67% in 2026.
- The last three Return on Capital Employed figures came in at 63.67% (Q1 2026), 67.62% (Q4 2025), and 57.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | -63.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.67% |
| Dec 31, 2025 | -67.62% |
| Sep 30, 2025 | -57.78% |
| Jun 30, 2025 | -54.92% |
| Mar 31, 2025 | -58.57% |
| Dec 31, 2024 | -50.43% |
| Sep 30, 2024 | -49.40% |
| Jun 30, 2024 | -79.17% |
| Mar 31, 2024 | -85.84% |
| Dec 31, 2023 | -64.41% |
| Sep 30, 2023 | -57.61% |
| Jun 30, 2023 | -52.02% |
| Mar 31, 2023 | -36.86% |
| Dec 31, 2022 | -40.28% |
| Sep 30, 2022 | -45.68% |
| Jun 30, 2022 | -38.49% |
| Mar 31, 2022 | -35.51% |
| Dec 31, 2021 | -32.83% |
| Sep 30, 2021 | -31.99% |
| Jun 30, 2021 | -37.51% |